DELFI Diagnostics CTO Dr. Amoolya Singh Honored as Influential Leader in Bay Area
In a recent announcement from DELFI Diagnostics, Dr. Amoolya Singh, the company’s Chief Technology Officer, has been recognized as one of the top leaders in the Bay Area business landscape, as per the San Francisco Business Times' list of Most Influential Women in Business for 2025. This honor is not a first for Dr. Singh, who was also featured on this prestigious list back in 2021, showcasing her continued impact in the biotech industry.
Dr. Singh became a key player at DELFI Diagnostics in December 2024, where she applies over two decades of expertise that resides at the intersection of biotechnology and computational science. DELFI Diagnostics specializes in developing innovative blood-based tests, utilizing cell-free DNA (cfDNA) fragmentomics for cancer detection. This technology stands out for its approach to improve cancer detection while making it accessible and affordable, especially for high-risk populations, including underserved communities.
Susan Tousi, the CEO of DELFI Diagnostics, praised Dr. Singh’s unique ability to integrate biological processes with computational techniques, stating, 'Amoolya excels at integrating biology and assay with computational science and software. Her collaborative approach to leadership ensures her teams can effectively push the boundaries of science to ultimately revolutionize healthcare.' This sentiment underscores the importance of teamwork and innovative thinking in the fast-evolving biotech sector.
The San Francisco Business Times recognizes exceptional business leaders who have shown substantial contributions to their companies and communities, confirming Dr. Singh’s notable selection from a pool of nearly 400 candidates. With her work deeply vested in the development of DELFI's technology, she expresses a strong commitment to making meaningful impacts through her research and development efforts. 'I am passionate about people and science, and my focus will always remain on making an impact in my work, while ensuring it serves others,' remarked Dr. Singh upon receiving this recognition.
DELFI Diagnostics employs an AI-driven approach that enables earlier interventions for high-risk populations, providing new avenues for timely treatment monitoring. Central to their innovations is the FirstLook Lung blood test, which was designed to enhance the early detection of lung cancer, a condition responsible for the highest mortality rate among all cancers in the United States. This test represents a breakthrough in cancer detection technologies, as it aims to identify lung cancer through a simple blood draw that aligns with routine testing practices.
Furthermore, the introduction of the DELFI-TF Assay showcases a dedicated effort to assist pharmaceutical companies in making informed decisions during oncology drug development processes. This technology not only provides crucial insights at various phases of the metastatic cancer journey but also improves the precision of treatment by offering continuous monitoring and resistance detection.
Looking forward, Dr. Singh is enthusiastic about further pursuing DELFI’s mission to provide innovative cancer detection solutions that could improve patient outcomes on a global scale. As she continues to lead the strategic technology development at DELFI Diagnostics, the emphasis will be placed on ensuring that their tests remain reliable, cost-effective, and focused on those in critical need.
As DELFI Diagnostics progresses, it remains committed to leveraging advanced technologies to tackle significant health challenges and improve the accuracy of cancer screenings for all. To stay updated on DELFI and its pioneering contributions to the cancer detection landscape, visit www.delfidiagnostics.com.
Overall, Dr. Amoolya Singh’s recognition is not just a personal accolade, but a testament to the crucial work being undertaken at DELFI Diagnostics, which continues to redefine standards in cancer detection methods and addresses some of the most pressing healthcare issues of our time.
Dr. Singh became a key player at DELFI Diagnostics in December 2024, where she applies over two decades of expertise that resides at the intersection of biotechnology and computational science. DELFI Diagnostics specializes in developing innovative blood-based tests, utilizing cell-free DNA (cfDNA) fragmentomics for cancer detection. This technology stands out for its approach to improve cancer detection while making it accessible and affordable, especially for high-risk populations, including underserved communities.
Susan Tousi, the CEO of DELFI Diagnostics, praised Dr. Singh’s unique ability to integrate biological processes with computational techniques, stating, 'Amoolya excels at integrating biology and assay with computational science and software. Her collaborative approach to leadership ensures her teams can effectively push the boundaries of science to ultimately revolutionize healthcare.' This sentiment underscores the importance of teamwork and innovative thinking in the fast-evolving biotech sector.
The San Francisco Business Times recognizes exceptional business leaders who have shown substantial contributions to their companies and communities, confirming Dr. Singh’s notable selection from a pool of nearly 400 candidates. With her work deeply vested in the development of DELFI's technology, she expresses a strong commitment to making meaningful impacts through her research and development efforts. 'I am passionate about people and science, and my focus will always remain on making an impact in my work, while ensuring it serves others,' remarked Dr. Singh upon receiving this recognition.
DELFI Diagnostics employs an AI-driven approach that enables earlier interventions for high-risk populations, providing new avenues for timely treatment monitoring. Central to their innovations is the FirstLook Lung blood test, which was designed to enhance the early detection of lung cancer, a condition responsible for the highest mortality rate among all cancers in the United States. This test represents a breakthrough in cancer detection technologies, as it aims to identify lung cancer through a simple blood draw that aligns with routine testing practices.
Furthermore, the introduction of the DELFI-TF Assay showcases a dedicated effort to assist pharmaceutical companies in making informed decisions during oncology drug development processes. This technology not only provides crucial insights at various phases of the metastatic cancer journey but also improves the precision of treatment by offering continuous monitoring and resistance detection.
Looking forward, Dr. Singh is enthusiastic about further pursuing DELFI’s mission to provide innovative cancer detection solutions that could improve patient outcomes on a global scale. As she continues to lead the strategic technology development at DELFI Diagnostics, the emphasis will be placed on ensuring that their tests remain reliable, cost-effective, and focused on those in critical need.
As DELFI Diagnostics progresses, it remains committed to leveraging advanced technologies to tackle significant health challenges and improve the accuracy of cancer screenings for all. To stay updated on DELFI and its pioneering contributions to the cancer detection landscape, visit www.delfidiagnostics.com.
Overall, Dr. Amoolya Singh’s recognition is not just a personal accolade, but a testament to the crucial work being undertaken at DELFI Diagnostics, which continues to redefine standards in cancer detection methods and addresses some of the most pressing healthcare issues of our time.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.